Business
LSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEMENT FOR THE ACQUISITION OF JUNO OTC
LSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEME...
About this update from Lsl Pharma Group Inc
[{"type":"text","content":"\n\n\nLSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEMENT FOR THE ACQUISITION OF JUNO OTC\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\n\nBOUCHERVILLE, QC, Dec. 23, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (The \"Corporation\" or \" LSL Pharma\"), a Canadian integrated pharmaceutical company, is pleased to announce that it has completed the closing of an initial tranche of its previously announced brokered private placement offering (the \"Brokered Offering\") of unsecured convertible debentures (the \"Debentures\") for total gross proceeds of $10,000,000 (the \"Offering\"). The Brokered Offering was led by Bloom Burton Securities Inc. (the \"Lead Agent\") on behalf of a syndicate including Research Capital Corporation and Leede Financial Inc. (collectively with the Lead Agent, the \"Agents\"). The Debentures were issued at a price of $1,000 per Debenture, for $10,000,000 in gross proceeds. The Debentures bear interest at 10.0% per annum, payable semi-annually in arrears, and mature on December 31, 2029 at which time the aggregate principal amount of the Debentures is repayable in cash. The principal amount of each Debenture is convertible into common shares of the Corporation (the \"Common Shares\") at a conversion price of $0.45 per Common Share.\nThe Offering has been upsized from the previously announced $11,000,000 to $12,000,000. The final $2,000,000 will close on a non-brokered basis concurrently with the Acquisition (as defined below).\nThe Brokered Offering was conducted pursuant to the terms of an agency agreement dated December 23, 2025 among the Corporation and the Agents (the \"Agency Agreement\"). In accordance with the terms of the Agency Agreement, in consideration for their services, the Agents received a total cash commission of $440,000 and a total of 400,000 broker warrants (the \"Broker Warrants\"). The Broker Warrants are exercisable for 24 months following the Offering Closing Date (as defined below) entitling the holder thereof to acquire one Common Share at a price of...